Skip to main content
Download PDF

Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction

BMC Veterinary Research volume 16, Article number: 356 (2020) Cite this article

Abstract

Background

Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses.

To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 µg/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively.

Results

DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID.

Conclusions

These findings provide evidence of restoration of DA and TH levels following treatment with pergolide. Equine PPID is a potential animal model of dopaminergic neurodegeneration, which could provide insight into human neurodegenerative diseases.

Background

Pituitary Pars Intermedia Dysfunction (PPID), a naturally occurring, slowly progressive neurodegenerative disorder affecting older horses and ponies, is the most commonly diagnosed equine endocrinopathy [1,2,3,4]. The hallmark clinical sign of PPID is hypertrichosis; an abnormally long, shaggy and often curly coat that fails to shed [5]. Additional signs associated with PPID include muscle wasting, abnormal fat distribution, lethargy, infertility, and an increased susceptibility to both parasitic and bacterial infections, which can lead to sinusitis, dermatitis, endoparasitism and laminitis [3, 4, 6,7,8,9]. The latter, laminitis, is a painful disorder of the feet that often necessitates euthanasia [4]. Several studies have also found that insulin dysregulation may accompany some cases of PPID, leading to glucose intolerance, type II diabetes, polydipsia and polyuria. Insulin dysregulation is also thought to predispose PPID-affected horses to laminitis [10]. Furthermore, up to a third of PPID-affected horses have been observed to display neurological deficits, including obtundation and seizure-like activity. Post-mortem examination of PPID afflicted horses reveals enlargement of the pituitary gland (PG) due to hyperplasia, hypertrophy and adenoma formation in the pars intermedia (PI). Some studies have reported up to a three-fold increase in PG weight in horses with PPID [1, 9].

The PI is composed of a single cell type known as a melanotrope, which produces pro-opiomelanocortin (POMC). Within melanotropes, POMC is differentially cleaved into the main secretory products of the PI; α-melanocyte-stimulating hormone (α-MSH), β-endorphin and corticotrophin-like intermediate lobe peptide (CLIP). In addition, a small amount of POMC may also be cleaved into adrenocorticotropin (ACTH); however, the majority of circulating ACTH is produced by the pars distalis of the PG [1, 10,11,12]. In horses with PPID, hyperplasia, hypertrophy and adenoma formation of PI melanotropes results in a large increase in POMC synthesis with corresponding increases in release of α-MSH, β-endorphin, CLIP, and a comparatively smaller increase in ACTH release [10]. Although the mechanism(s) by which these POMC-derived peptides lead to development of clinical signs is not well understood, it may involve interactions between α-MSH, β-endorphin and ACTH. For example, α-MSH and β-endorphin are capable of inducing a six-fold increase in the steroidogenic properties of ACTH [13]. Thus, a small increase in ACTH coupled with larger increases in potentiating peptides, α-MSH and β-endorphin, may be sufficient to stimulate adrenocortical steroidogenesis, resulting in increased plasma cortisol levels and loss of circadian rhythmicity of cortisol secretion [10, 14]. Hence, horses with PPID are commonly referred to as having equine Cushing’s disease. However, Cushing’s disease parameters do not incorporate all the features of PPID and thus does not adequately explain equine PPID.

The exact cause of PPID is unknown, however, loss of dopaminergic innervation to the PI seems to be critical in development of the disorder. Normally, dopaminergic innervation from the periventricular nucleus (PVN) of the hypothalamus inhibits POMC expression in the PI via activation of dopamine (DA) D2 receptors on melanotropes [11, 12, 15, 16]. In horses with PPID, progressive loss of dopaminergic inhibition results in an increase in circulating POMC derivatives. Although the mechanisms for loss of dopaminergic innervation remain uncertain, oxidative stress and mitochondrial dysfunction in PI have been suggested to play a role [1, 17]. Concentrations of DA and DA metabolites have been found to be 9-fold lower in PI tissue of horses with PPID as compared with normal horses [18]. In addition, loss of hypothalamic (periventricular nuclei, PVN) dopaminergic neurons has been found in PPID-affected horses, as compared to aged horses without PPID [1]. Further, DA D2 receptor knockout mice develop PI hypertrophy and hyperplasia similar to the histopathologic changes in the PG found with PPID in horses [19].

In horses with PPID, PI tissue has further been shown to have increased amounts of immunochemical staining for 3-nitrotyrosine [1]. In human medicine, accumulation of 3-nitrotyrosine occurs in neurodegenerative diseases such as Parkinson’s disease [20,21,22], but the significance is equivocal since similar findings have been described in healthy aged individuals [23]. In familial Parkinson’s disease, a mutation in the gene encoding α-synuclein has been correlated with cytoplasmic accumulation of α-synuclein in Lewy Bodies that is thought to contribute to degeneration of nigrostriatal dopaminergic neurons [24,25,26]. Interestingly, nitrated α-synuclein has been shown to be more neurotoxic than native α-synuclein [27]. Horses with PPID have higher levels of nitrated α-synuclein in the dopaminergic nerve terminals within the PI compared with healthy horses [1]. Decreased TH immunoreactivity has also been described in the PI of PPID-affected horses [1, 17, 18]. Loss of TH immunoreactivity also occurs in Parkinson’s disease, although the role of this finding in the pathophysiology of Parkinson’s disease is not defined [28]. Equine PPID shares similar neurochemical perturbations observed in Parkinson’s disease including oxidative stress, antioxidant deficiency, nitrated α-synuclein accumulation and loss of TH immunoreactivity. Thus, equine PPID may have potential as an animal model to better understand the neurobiology of dopaminergic neurodegenerative diseases, including Parkinson’s disease.

In humans, pharmacotherapy of Parkinson’s disease is primarily aimed at restoring dopaminergic neurotransmission in the corpus striatum. Currently, the most effective treatment is levodopa in combination with a peripheral decarboxylase inhibitor [29]. Levodopa is metabolized into DA in dopaminergic neurons, temporarily restoring levels of this endogenous neurotransmitter. Long-term use of levodopa is associated with fluctuation of motor responses and dyskinesias [30, 31], thus narrowing the therapeutic window [32]. Levodopa is also known to be neurotoxic in vitro [33]. In vivo studies demonstrate formation of cytotoxic free radicals with decarboxylation of levodopa. As such, increasing levels of DA through administration of levodopa could potentially cause oxidative damage to surviving dopaminergic neurons, creating a risk of eventually exacerbating the disease [34, 35]. DA agonists were introduced to mimic the endogenous neurotransmitter [36], and as an adjunct to levodopa treatment in patients exhibiting fluctuating motor responses and dyskinesias due to chronic use of levodopa [37,38,39]. DA agonist administration reduces the dose of levodopa required by 20%-30% as well as the disabling complications. There are two subclasses of DA agonists targeting DA D2-type receptors: ergoline agonists (pergolide, bromocriptine, lisuride, and cabergoline) and non-ergoline agonists (ropinirole and pramipexole). DA agonists are not metabolized by oxidative pathways and do not generate cytotoxic free radicals associated with metabolism of DA or levodopa. These drugs may further protect dopaminergic neurons from injury resulting from levodopa by suppressing endogenous DA release. DA agonists cause less motor complications versus levodopa, possibly due to a longer half-life and differences in receptor selectivity [40].

Pergolide has been shown to improve symptoms of Parkinson’s disease alone or in combination with levodopa and may be more effective than bromocriptine [41,42,43]. This could be explained by the action of pergolide on both DA D1 and DA D2-type receptors, whereas bromocriptine is a DA D2 agonist with weak DA D1 antagonistic properties [41]. In veterinary medicine, administration of pergolide is commonly used as a therapeutic agent in horses afflicted with PPID. Pergolide treatment results in a decrease in plasma concentrations of POMC derived peptides and notable clinical improvement [44]. We hypothesized that DA concentrations and TH expression levels are greater in PI tissue collected from PPID-affected horses treated with pergolide than those in PI tissues collected from untreated PPID-affected horses. PPID causes depletion of DA and treatment with a DA agonist would allow the dopaminergic neurons to replenish DA storage in vesicles. In rodents, activation of DA D1 and D2 receptors has been shown to contribute to increasing TH enzymatic activity [45]. Thus, in the current study, DA concentrations and TH expression levels in PI tissue were compared between PPID-affected horses treated with pergolide over a period of 6 months, untreated PPID-affected horses, untreated aged horses without clinical signs of PPID, and untreated young horses. Our results suggest that equine PPID is a potential animal model for DA neurodegeneration which could give insights to Parkinson’s disease and provides additional evidence of the therapeutic benefits of dopaminergic receptor agonists.

Results

This study focused on measuring DA concentrations in PI tissue collected from horses of different age and disease status to understand the impact of DA agonist treatment in PPID-affected horses. A summary of groups with the associated PG weights and histologic score are presented in Table 1. All 10 PPID-affected horses had hypertrichosis and other clinical signs of PPID. Treatment with pergolide did not reduce the weight of the PGs (Table 1). DA concentrations were higher for the healthy young horses (5.6 ± 1.9 ng/mg) compared with all other groups, with mean DA concentration in PI tissue collected from all aged horses about 5 times less than that of young horses (Fig. 1).

Fig. 1
figure 1

A 6-month treatment with pergolide restores the concentration of DA in the pars intermedia of PPID horses to the level of comparably aged horses without PPID. DA concentrations were measured in the pars intermedia of pituitary glands using HPLC-ED. Pituitary glands were collected from horse controls (young and old normal control horses), PPID untreated horses, and PPID afflicted horses that had received treatment with pergolide (DA agonist) at 2 µg/kg per os for 6 months. Columns represent mean DA concentrations + S.E.M. * Values that are significantly different from the young control group (p < 0.05)

Full size image
Table 1 Mean horse age and pituitary gland weights and histologic grades for each group
Full size table

Mean DA concentration was lowest in the PPID untreated group (0.06 ± 0.06 ng/mg) (Fig. 1). Interestingly, there was no difference between PI DA concentrations in pergolide treated PPID horses (0.60 ± 0.29 ng/mg) as compared with similar aged horses without clinical signs of PPID (0.82 ± 0.37 ng/mg), suggesting treatment with pergolide restored DA concentrations in the PI to age-appropriate levels.

In this study, we investigated if there is loss of TH expressions levels with neurodegeneration of hypothalamic PVN dopaminergic neurons that innervate the PI. TH expression levels were decreased in untreated-PPID horses (Fig. 2). However, there was no significant difference in TH concentration in PI tissue between the young and aged horses without PPID. PPID horses treated with pergolide showed similar PI TH expression levels as young and aged horses without PPID (Fig. 2). These results suggest that pergolide treatment re-establishes TH expression levels in PI of PPID-affected horses.

Fig. 2
figure 2

TH expression levels are re-established in the pars intermedia of PPID horses on a 6-month pergolide regimen. TH expression levels were determined in the pars intermedia of pituitary glands using western blot. Pituitary glands were collected from horse controls (young and old normal control horses), PPID untreated horses, and PPID afflicted horses that had received treatment with pergolide (DA agonist) at 2 µg/kg per os for 6 months. Columns represent mean TH concentrations normalized to β-actin + S.E.M. * The PPID-untreated value is significantly different from the young and old control groups as well as the PPID-treated group (p < 0.05)

Full size image

Discussion

We hypothesized that pergolide treatment would re-establish DA and TH concentrations in PI tissue in horses with PPID. Our data are consistent with this hypothesis; we demonstrated that horses with PPID that received pergolide treatment had partial (compared with young horses) and complete (compared with aged horses) recovery of DA concentration in the PI. However, this study would need to be repeated with higher numbers of horses per group to confirm the absence of significant difference in DA concentration between PPID and non PPID horses. In addition, pergolide treated horses showed complete recovery of TH protein concentrations in the PI. Loss of hypothalamic dopaminergic innervation has a role in PPID physiopathology that has not yet been fully defined. Administration of DA agonists is a logical therapeutic strategy for horses with PPID [46,47,48], which our data further reinforce. Previous work has shown that PPID horses treated with DA agonists have decreased levels of POMC peptides and adrenocorticotropic hormone (ACTH) in the PI, and cortisol concentrations in plasma [14, 46, 49].

Our study focused on the determination of DA concentration in the PI because the PG receives direct innervation from the dopaminergic neurons of the PVN of the hypothalamus. These axons project through the infundibular stalk, travel along the periphery of the nerve pathway and then terminate in the PI. At this site, DA, released by the periventricular nerve terminals, interacts with melanotrope DA D2 receptors causing a decrease in POMC-derived hormone synthesis and release, as well as inhibition of cell division [50]. There is mounting evidence that PPID is a neurodegenerative disorder characterized by loss of DA neurons and, subsequently, dopaminergic input to PI melanotropes. The lack of endogenous DA-mediated inhibition of PI POMC production in PPID-affected equids may also result in multiclonal expansion which could explain (in addition to the fluctuation of cortisol release in the blood stream [14]) PI hyperplasia and formation of multifocal adenomas via persistent hormonal stimulation. Dorsal expansion of the PG and compression of surrounding structures including the hypothalamus and infundibular stalk might explain, in part, loss of PVN dopaminergic axon terminals which decreases the concentration of DA and DA-metabolites [1]. In the present study, untreated PPID-affected horses had ~ 10-fold less DA in PI tissue as measured by HPLC-ED, which provides biochemical confirmation of the immunohistochemical data published by McFarlane et al. [1].

Our study provides additional evidence that PPID-affected horses have significantly decreased PI DA concentrations. Interestingly, aged horses without PPID have reduced DA concentrations in comparison to young horses. A previous study identified reduced numbers of dopaminergic cell bodies in the hypothalamic PVN of PPID-affected horses compared to healthy aged horses [1]. Aging decreases DA concentrations in the spinal cord of adult mares compared to pre-pubertal females [51]. In the present study, PI DA concentrations of PPID-affected horses treated with pergolide were not restored to the same level as young horses. This may be due to normal age-related loss of dopaminergic neurons, as supported by enlargement of the PI in aged horses without clinical signs of PPID. It would have been useful to include a group of aged horses without PPID that received pergolide treatment to provide further evidence of DA restoration in the context of age-related DA-neurodegeneration.

In a previous study, TH immunoreactivity was reduced in PI tissues obtained from PPID horses and no difference was detected in TH between young and aged horses using immunohistochemistry techniques [1]. This finding is consistent with a role for dopaminergic neurodegeneration in the etiology of PPID and prompted evaluation of TH expression levels in PI tissues from different horse groups included in this study. Similarly, TH protein expression level by Western blot analyses in the current study was similar in young and aged horses. Mechanisms regulating TH expression and DA synthesis are distinctly different, which might explain the difference observed between and TH concentrations (no change) and DA concentrations (decreased) in the aged horses without PPID. TH is an enzyme that catalyzes the first and rate-limiting step in biosynthesis of catecholamines (such as DA), converting tyrosine to L-dihydroxyphenylalanine (L-DOPA). TH is localized in presynaptic catecholaminergic neurons in general, including noradrenergic neurons, and not solely expressed in dopaminergic neurons [52]. TH activity is controlled by direct regulation (short term regulation) of enzyme activity (allosteric regulation, catecholamine feedback inhibition and phosphorylation) and gene transcription (long term regulation) [52]. In the present study, TH expression levels in aged horses remained similar to those of young horses in contrast to lower DA concentrations in aged horses. This finding highlights the independent synthetic pathways, turn over and genetic expression of DA receptors and TH in equid PI. Activation of DA D1 and D2 receptors in rodents has been shown to increase TH S-nitrosylation and its enzymatic activity [45]. It would be interesting in a further study to assess TH enzymatic activity and posttranslational modifications such as phosphorylation and nitrosylation in PI of young, old, and PPID-affected horses to determine if one of these modifications could potentially result in a difference in TH activity. This might explain the low concentration of DA, despite normal TH expression levels in aged horses.

In the current study, a 6-month oral treatment with pergolide re-established the concentrations of DA and TH in PI tissue of PPID-affected horses to levels equivalent with aged horses without clinical signs of PPID. In Parkinson’s disease, dysfunction of the nigrostriatal tract begins with an initial loss of TH expressing nigrostriatal axon terminals and is followed by actual loss of dopaminergic neurons in the substantia nigra [53, 54]. Altered DA synthesis in the striatum causes loss of fine motor skills [53]. Novel therapeutic interventions in Parkinson’s disease focus on halting or reversing neurodegeneration of the nigrostriatal DA neuronal tract with gene therapy. Aromatic l-amino acid decarboxylase (AADC) gene therapy with an adeno-associated viral vector that can convert peripheral l-dopa to dopamine has been shown to restore DA production in Parkinsonian monkeys [55]. Previous work in the 6-hydroxydopamine rat model of experimental Parkinson’s disease demonstrated complete normalization of striatal TH activity following an intravenous administration of transferrin receptor monoclonal antibody (TfRmAb) targeted pegylated immunoliposomes carrying a TH expression plasmid [56]. Our data provide initial evidence that a DA agonist could actually re-establish TH protein expression in dopaminergic neurons. The specific mechanism for increases in DA concentration and TH expression level following pergolide treatment remains unclear. One explanation could be that PPID causes depletion of DA and treatment with a DA agonist allows dopaminergic neurons to replenish DA storage in vesicles. Activation of DA D1 and D2 receptors may lead to increase of TH enzymatic activity. Our data further suggest that similar pharmacological strategies could be employed to restore DA biosynthesis in Parkinson’s disease.

Conclusions

The results of this study demonstrate that pergolide, a DA agonist, re-establishes DA and TH levels in the PI of PPID-affected horses. The ability of pergolide to re-establish a dopaminergic phenotype of aged horses without PPID provides support for further investigation of the therapeutic efficacy of dopaminergic receptor agonists for other dopaminergic neurodegenerative disorders, including Parkinson’s disease.

Methods

Animals

Horses were owned by another individual/farm and informed written consent was obtained from the owners. All procedures were approved by the Michigan State University Institutional Animal Care and Use Committee (AUF 11/08-191-00). Horses were sedated with xylazine HCl (0.6 mg/kg, IV) and Na pentobarbital (100 mg/kg, IV) was administrated for euthanasia. Pituitary glands were removed within 30 min of euthanasia from 18 horses in the fall (August to November): six PPID-affected horses (26 ± 3 years) that were treated with pergolide at 2 µg/kg per os once daily for 6 months, four untreated PPID-affected horses (27 ± 4 [SD] years), four aged (25 ± 5 years) horses without signs of PPID, and four young (5 ± 2 years) normal horses.

PPID status

PPID status was confirmed by presence of clinical signs, notably hypertrichosis. Postmortem histologic examination of the PG was performed by two veterinary pathologists using the histologic grades established by Miller et al. as follows: (1) normal; (2) focal to multifocal PI hypertrophy or hyperplasia; (3) diffuse PI adenomatous hyperplasia; (4) PI adenomatous hyperplasia with microadenomas 1–5 mm in diameter; (5) adenoma > 5 mm in the PI [3].

Tissue preparation

Frozen PGs (-80°C) were examined to determine rostral-caudal orientation and sagittal sections (500 µM thick) were sliced from each PG starting from an abaxial border. Central sections were viewed under a dissecting microscope in which the three separate lobes of the PG (pars distalis, PI and pars nervosa) could be discerned. Samples (two 18 gauge needle punches) were obtained from the PI and prepared for neurochemical analyses. Samples were placed into microtubes containing 65 µL of ice cold 0.1M phosphate-citrate buffer containing 15% methanol. Tissues were sonicated with three short (≈ 1 sec) bursts to release monoamines stored within vesicles. Samples were next centrifuged for 1 minute. Supernatants (containing monoamines) were extracted with a 100 µl Hamilton syringe, placed in a new microtube, and centrifuged for 5–10 sec. A volume of 100 µL 0.1 M NaOH was then pipetted into the microtube containing pellet (proteins). Supernatants were stored at -20 °C until HPLC-ED analysis and pellets were stored at room temperature until Lowry protein assay was conducted.

Dopamine (DA) concentration determination by high performance liquid chromatography with electrochemical detection (HPLC-ED)

For measurement of DA using HPLC-ED, 10 µL of each supernatant were injected into C-18 columns. The HPLC mobile phase was a 20% methanol and 0.02% SOS solution with a pH of 2.65. PI samples were compared to a 1 ng “7-mix” standard containing dihydroxyphenylethylene glycol (DOPEG), norepinephrine (NE), 3,4-dihydroxyphenylacetic acid (DOPAC), homovallinic acid (HVA), DA, serotonin (5HT) and 5-hydroxyindoleacetic acid (5HIAA). PI DA concentrations were expressed in ng/mg protein, using protein content values obtained from a Lowry protein assay.

Tyrosine-hydroxylase (TH) expression levels by western blot analysis

PI protein extracts (15 µg) were solubilized in SDS-PAGE buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.00125% bromophenol blue, and 15% β-mercaptoethanol). The extracts were boiled for 5 min, separated (15 µg) on 10% SDS-PAGE electrophoresis gel and transferred onto a nitrocellulose membrane. All membranes were blocked and incubated with an appropriate dilution of the primary antibody: TH antibody (1:2000; Millipore AB152) and β-actin (1:1000; Cell Signaling #3700). Membranes were next washed and incubated with a horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG secondary antibody (1: 2500; (Cell Signaling) followed by chemiluminescent detection, using an enhanced chemiluminescence (ECL) detection kit (ThermoFisher Scientific). Films were scanned and the density of each band was measured with Image J software. TH expression levels were normalized to β-actin.

Statistical analysis

Factorial-ANOVA statistical comparisons between groups were made using Sigma Stat software version 2.03 (SysStat Software, Inc.). A p value of less than or equal to 0.05 was considered significant. If a statistical difference was detected, post hoc analysis was performed using Tukey’s Test for between group comparisons.

Availability of data and materials

The data used and/or analyzed in the present study are available from the corresponding author on reasonable request.

Abbreviations

5HIAA:

5-hydroxyindoleacetic acid

5HT:

Serotonin

α-MSH:

α-melanocyte-stimulating hormone

AADC:

Aromatic l-amino acid decarboxylase

ACTH:

Adrenocorticotropic hormone

CLIP:

Corticotrophin-like intermediate lobe peptide

DA:

Dopamine

DOPAC:

3,4-dihydroxyphenylacetic acid

DOPEG:

Dihydroxyphenylethylene glycol

ECL:

Enhanced chemiluminescence

HPLC-ED:

High performance liquid chromatography with electrochemical detection

HVA:

Homovallinic acid

L-DOPA:

L-dihydroxyphenylalanine

NE:

Norepinephrine

ODST:

Overnight dexamethasone suppression test

PI:

Pars intermedia

PG:

Pituitary gland

POMC:

Pro-opiomelanocortin

PPID:

Pituitary pars intermedia dysfunction

PVN:

Periventricular nucleus

TfRmAb:

Transferrin receptor monoclonal antibody

TH:

Thyrosine hydroxylase

References

  1. McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol. 2005;17:73–80.

    Article  CAS  PubMed  Google Scholar 

  2. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989–1999). J Am Vet Med Assoc. 2003;223:93–8.

    Article  PubMed  Google Scholar 

  3. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol. 2008;45:26–38.

    Article  CAS  PubMed  Google Scholar 

  4. Schott HC 2. Pituitary pars intermedia dysfunction: equine Cushing’s disease. Vet Clin North Am Equine Pract. 2002;18:237–70. nd. .

  5. Innera M, Petersen AD, Desjardins DR, Steficek BA, Rosser EJ Jr, Schott HC 2nd. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses. Vet Dermatol. 2013;24:212–217 e246-217.

    Google Scholar 

  6. van der Kolk JH, Kalsbeek HC, van Garderen E, Wensing T, Breukink HJ. Equine pituitary neoplasia: a clinical report of 21 cases (1990–1992). Vet Rec. 1993;133:594–7.

    PubMed  Google Scholar 

  7. Hillyer MH, Taylor FGRT, Mair TS, Murphy D, Watson TDG, Love S. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Edu. 1992;4:131–4.

    Article  Google Scholar 

  8. Couetil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med. 1996;10:1–6.

    Article  CAS  PubMed  Google Scholar 

  9. Heinrichs M, Baumgartner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol. 1990;27:419–25.

    Article  CAS  PubMed  Google Scholar 

  10. Spelta CW. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management. Vet Med (Auckl). 2015;6:293–300.

    Google Scholar 

  11. Kemppainen RJ, Peterson ME. Regulation of alpha-melanocyte-stimulating hormone secretion from the pars intermedia of domestic cats. Am J Vet Res. 1999;60:245–9.

    CAS  PubMed  Google Scholar 

  12. Kemppainen RJ, Zerbe CA, Sartin JL. Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells. Endocrinology. 1989;124:2208–17.

    Article  CAS  PubMed  Google Scholar 

  13. Dybdal NO, Hargreaves KM, Madigan JE, Gribble DH, Kennedy PC, Stabenfeldt GH. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc. 1994;204:627–32.

    CAS  PubMed  Google Scholar 

  14. Morgan RA, Keen JA, Homer N, Nixon M, McKinnon-Garvin AM, Moses-Williams JA, Davis SR, Hadoke PWF, Walker BR. Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction. Endocrinology. 2018;159:3791–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Luppi PH, Sakai K, Salvert D, Berod A, Jouvet M. Periventricular dopaminergic neurons terminating in the neuro-intermediate lobe of the cat hypophysis. J Comp Neurol. 1986;244:204–12.

    Article  CAS  PubMed  Google Scholar 

  16. Goudreau JL, Falls WM, Lookingland KJ, Moore KE. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuroendocrinology. 1995;62:147–54.

    Article  CAS  PubMed  Google Scholar 

  17. McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am J Vet Res. 2005;66:2065–72.

    Article  CAS  PubMed  Google Scholar 

  18. Millington WR, Dybdal NO, Dawson R Jr, Manzini C, Mueller GP. Equine Cushing’s disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary. Endocrinology. 1988;123:1598–604.

    Article  CAS  PubMed  Google Scholar 

  19. Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing’s-like syndrome in mice. Mol Endocrinol. 1998;12:1133–9.

    CAS  PubMed  Google Scholar 

  20. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res. 2000;25:1315–41.

    Article  CAS  PubMed  Google Scholar 

  21. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40:959–75.

    Article  CAS  PubMed  Google Scholar 

  22. Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal. 2000;2:449–60.

    Article  CAS  PubMed  Google Scholar 

  23. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–47.

    Article  CAS  PubMed  Google Scholar 

  24. Lee PC, Bordelon Y, Bronstein J, Sinsheimer JS, Farrer M, Ritz B. Head injury, alpha-synuclein genetic variability and Parkinson’s disease. Eur J Neurol. 2015;22:874–8.

    Article  CAS  PubMed  Google Scholar 

  25. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–7.

    Article  CAS  PubMed  Google Scholar 

  26. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. Induction of neuronal death by alpha-synuclein. Eur J Neurosci. 2000;12:3073–7.

    Article  CAS  PubMed  Google Scholar 

  27. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985–9.

    Article  CAS  PubMed  Google Scholar 

  28. Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Human tyrosine hydroxylase in Parkinson’s disease and in related disorders. J Neural Transm (Vienna). 2019;126:397–409.

    Article  CAS  Google Scholar 

  29. Silva MA, Mattern C, Hacker R, Tomaz C, Huston JP, Schwarting RK. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse. 1997;27:294–302.

    Article  CAS  PubMed  Google Scholar 

  30. Sweet RD, McDowell FH. Five years’ treatment of Parkinson’s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med. 1975;83:456–63.

    Article  CAS  PubMed  Google Scholar 

  31. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979;29:1253–60.

    Article  CAS  PubMed  Google Scholar 

  32. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37:23–7.

    Article  CAS  PubMed  Google Scholar 

  33. Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Ann Neurol. 1998;44:149–54.

    Article  Google Scholar 

  34. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–23.

    Article  CAS  PubMed  Google Scholar 

  35. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord. 1997;12:634–8.

    Article  CAS  PubMed  Google Scholar 

  36. Quinn N. Drug treatment of Parkinson’s disease. BMJ. 1995;310:575–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Uitti RJ, Ahlskog JE. Comparative Review of Dopamine Receptor Agonists in Parkinson’s Disease. CNS Drugs. 1996;5:369–88.

    Article  CAS  PubMed  Google Scholar 

  38. Fischer PA. Treatment strategies in Parkinson’s disease after a quarter century experiences with L-DOPA therapy. J Neural Transm Suppl. 1995;46:381–9.

    CAS  PubMed  Google Scholar 

  39. Oertel WH, Quinn NP. Parkinson’s disease: drug therapy. Baillieres Clin Neurol. 1997;6:89–108.

    CAS  PubMed  Google Scholar 

  40. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998;13:39–45.

    Article  CAS  PubMed  Google Scholar 

  41. Boas JWP J, Dupont E, Mikkelsen B, Wermuth L. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study. Eur J Neurol. 1996;3:44–9.

    Article  Google Scholar 

  42. Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E, et al. Pergolide compared with bromocriptine in Parkinson’s disease: a multicenter, crossover, controlled study. Mov Disord. 1994;9:431–6.

    Article  CAS  PubMed  Google Scholar 

  43. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord. 1995;10:668–71.

    Article  CAS  PubMed  Google Scholar 

  44. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing’s disease). J Vet Intern Med. 2002;16:742–6.

    PubMed  Google Scholar 

  45. Wang Y, Sung CC, Chung KK. Novel enhancement mechanism of tyrosine hydroxylase enzymatic activity by nitric oxide through S-nitrosylation. Sci Rep. 2017;7:44154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract. 2011;27:93–113.

    Article  PubMed  Google Scholar 

  47. McFarlane D, Banse H, Knych HK, Maxwell LK. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. J Vet Pharmacol Ther. 2017;40:158–64.

    Article  CAS  PubMed  Google Scholar 

  48. Durham AE. Therapeutics for Equine Endocrine Disorders. Vet Clin North Am Equine Pract. 2017;33:127–39.

    Article  PubMed  Google Scholar 

  49. Gehlert DR, Bishop JF, Schafer MP, Chronwall BM. Rat intermediate lobe in culture: dopaminergic regulation of POMC biosynthesis and cell proliferation. Peptides. 1988;9(Suppl 1):161–8.

    Article  PubMed  Google Scholar 

  50. McFarlane D. Pathophysiology and clinical features of pituitary pars intermedia dysfunction. Veterinary Education. 2014;26:592–8.

    Article  Google Scholar 

  51. Melrose PA, Walker RF, Douglas RH. Dopamine in the cerebrospinal fluid of prepubertal and adult horses. Brain Behav Evol. 1990;35:98–106.

    Article  CAS  PubMed  Google Scholar 

  52. Fujisawa H, Okuno S. Regulatory mechanism of tyrosine hydroxylase activity. Biochem Biophys Res Commun. 2005;338:271–6.

    Article  CAS  PubMed  Google Scholar 

  53. Booij J, de Bruin K, de Win MM, Lavini C, den Heeten GJ, Habraken JB. Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. Nucl Med Biol. 2003;30:643–9.

    Article  CAS  PubMed  Google Scholar 

  54. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136:2419–31.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164:2–14.

    Article  CAS  PubMed  Google Scholar 

  56. Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy. NeuroRx. 2005;2:129–38.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Schott IIHC, Patterson JS, Howey EB, Benskey MJ, Goudreau JL, Lookingland KJ. Dopamine and tyrosine hydroxylase concentrations in pars intermedia tissue of horses with pituitary pars intermedia dysfunction with and without pergolide treatment. J Vet Intern Med. 2012;26(3):736.

    Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the abstract publication (abstract E-31) of this study at the 2012 ACVIM Forum Research Abstracts Program [57].

Funding

The present study was financially supported by Michigan State University College of Veterinary Medicine Endowed Research Funds and Boehringer-Ingelheim Animal Health USA.

Author information

Authors and Affiliations

  1. Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, 48824, MI, USA

    Jessica S. Fortin, Jon S. Patterson & Erin B. Howey

  2. Department of Pharmacology and Toxicology, Neuroscience Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA

    Matthew J. Benskey, Keith J. Lookingland & John L. Goudreau

  3. Neurology and Ophthalmology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA

    John L. Goudreau

  4. Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, MI, 48824, USA

    Harold C. Schott II

Authors
  1. Jessica S. Fortin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J. Benskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith J. Lookingland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jon S. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erin B. Howey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John L. Goudreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Harold C. Schott II
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KJL, JSP, JLG, and HCSII designed the research. MJB, KJL, JSP, EBH, and HCSII performed research. JSF, MJB, KJL, JSP, EBH, JLG, and HCSII analyzed the data. JSF, MJB, and KJL. prepared figures. JSF and HCSII wrote the paper. All the authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Corresponding authors

Correspondence to Jessica S. Fortin or Harold C. Schott II.

Ethics declarations

Ethics approval and consent to participate

The protocol was approved in advance by the Michigan State University and complied with its Institutional Animal Care and Use Committee (approval number AUF 11/08-191-00). Horses were owned by another individual and informed written consent was obtained from all horse owners.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fortin, J.S., Benskey, M.J., Lookingland, K.J. et al. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. BMC Vet Res 16, 356 (2020). https://doi.org/10.1186/s12917-020-02565-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12917-020-02565-3

Keywords

  • Dopamine agonist
  • Equine
  • Parkinson disease animal model
  • Pituitary pars intermedia adenoma

BMC Veterinary Research

ISSN: 1746-6148

Contact us